GlassScriptPhysician profile
Susan Perdue Schultz
NPI 1508256975
$2,302.25
in general payments reported to CMS, 2019-2025
26 companies · $489 in 2025
The $489 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $186 · 2022: $711 · 2023: $450 · 2024: $465 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,404.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $355.76 | 2022-2024 | |
| Genzyme Corporation | $234.31 | 2022-2024 | |
| Axsome Therapeutics, INC. | $154.35 | 2024-2025 | Symbravo, Auvelity |
| Astrazeneca Pharmaceuticals LP | $139.36 | 2021-2022 | |
| Abbvie INC. | $135.76 | 2021-2023 | |
| Hologic Sales and Service, LLC | $130.60 | 2025 | Aptima |
| Xeris Pharmaceuticals, INC. | $124.99 | 2023 | Gvoke Hypopen |
| Stryker Corporation | $124.99 | 2025 | Mild Device Kit |
| Sk Life Science, INC. | $118.45 | 2021 | |
| Sage Therapeutics, LLC | $108.65 | 2025 | |
| Biogen, INC. | $99.99 | 2022 | |
| Novo Nordisk INC | $96.00 | 2022 | |
| Edwards Lifesciences Corporation | $87.56 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abbott Laboratories | $85.03 | 2023-2024 | Freestyle Libre 3 |
| Ucb, INC. | $72.80 | 2024 | Briviact |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $46.90 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.14 | 2023-2024 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $27.66 | 2023 | Jynarque |
| Janssen Pharmaceuticals, INC | $25.40 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.49 | 2023 | |
| Merck Sharp & Dohme LLC | $16.00 | 2024 | M-M-R II, Capvaxive, Gardasil 9 |
| Lilly USA, LLC | $15.90 | 2024 | Mounjaro |
| Currax Pharmaceuticals LLC | $14.97 | 2023 | Contrave, Nexlizet, Onzetra Xsail |
| Pfizer INC. | $14.53 | 2024 | |
| Amgen INC. | $13.00 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $11.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Perdue Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.